Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Maruho Co., Ltd. clinical trials
The registry lists 39 studies whose lead sponsor is Maruho Co., Ltd. or one of 2 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 13, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Maruho Co., Ltd..
- Maruho Co., Ltd.27 studiesSame company
Something wrong?
- Maruho Europe Limited6 studies →Regional office
Something wrong?
- Maruho North America Inc.6 studies →Regional office
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 39 of 39.
- An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic SclerosisCompletedNCT05214794Phase 2
- Phase III Study of ASP2151 in Herpes Simplex PatientsCompletedNCT01959295Phase 3
- Open-label Study of ASP2151 in Herpes Simplex PatientsCompletedNCT02209324Phase 3
- A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common WartsCompletedNCT03259620Phase 3
- A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common WartsCompletedNCT02971891Phase 3
- A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque PsoriasisWithdrawnNCT02970331Phase 2
- Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus VehicleCompletedNCT02576860Phase 3
- Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus VehicleCompletedNCT02547441Phase 3
- Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical GelCompletedNCT02576847Phase 3
- Drug-Drug Interaction Study: ASP2151 and CiclosporinCompletedNCT02280421Phase 1
Sponsor listed in the registry: Maruho Europe Limited
- Topical Ionic Contra-Viral Therapy in Actinic KeratosisStatus unknownNCT03684772Phase 2
- Omiganan Twice a Day (BID) in Patients With Facial Seborrheic DermatitisStatus unknownNCT03688971Phase 2
- ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent PatientsTerminatedNCT03334240Phase 2
- Drug-Drug Interaction Study: ASP2151 and MontelukastCompletedNCT02321748Phase 1
Sponsor listed in the registry: Maruho Europe Limited
- Drug-Drug Interaction Study: ASP2151 and RitonavirCompletedNCT02223351Phase 1
Sponsor listed in the registry: Maruho Europe Limited
- Drug-Drug Interaction Study: ASP2151 and BupropionCompletedNCT02369172Phase 1
Sponsor listed in the registry: Maruho Europe Limited
- Drug-Drug Interaction Study: ASP2151 and MidazolamCompletedNCT02403635Phase 1
Sponsor listed in the registry: Maruho Europe Limited
- Phase III Study of ASP2151 in Herpes Zoster PatientsCompletedNCT01959841Phase 3
- Pharmacodynamics of Omiganan BID in Patients With Atopic DermatitisCompletedNCT03091426Phase 2
- Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVINCompletedNCT02596074Phase 2
- Topical Challenge With Omiganan and Imiquimod in Healthy VolunteersCompletedNCT03071679Phase 1
- Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital WartsCompletedNCT02849262Phase 2
- A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne VulgarisCompletedNCT02571998Phase 2
- Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic DermatitisCompletedNCT02456480Phase 2
- A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.CompletedNCT02333643Phase 2
- Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis PatientsCompletedNCT01989429Phase 3
Sponsor listed in the registry: Maruho Europe Limited
- Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis PatientsCompletedNCT01301157Phase 2
- Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne VulgarisCompletedNCT02066545Phase 2
- Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque PsoriasisCompletedNCT01908595Phase 3
Sponsor listed in the registry: Maruho North America Inc.
- Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisCompletedNCT01878461Phase 3
Sponsor listed in the registry: Maruho North America Inc.
- Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisCompletedNCT01873677Phase 3
Sponsor listed in the registry: Maruho North America Inc.
- Skin Safety Study to Evaluate the Sensitizing Potential in Healthy VolunteersCompletedNCT02256930Phase 1
Sponsor listed in the registry: Maruho North America Inc.
- A Twelve Week Safety and Efficacy Study in RosaceaCompletedNCT01784133Phase 2
- Skin Safety Study to Evaluate the Irritation Potential in Healthy VolunteersCompletedNCT02227069Phase 1
Sponsor listed in the registry: Maruho North America Inc.
- First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous WartsCompletedNCT02106260Phase 1/2
- A 21 Day Pharmacokinetics Study in Papulopustular RosaceaCompletedNCT02028286Phase 1
- Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis PatientsCompletedNCT01844973Phase 1
Sponsor listed in the registry: Maruho North America Inc.
- Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic DermatitisCompletedNCT00980629Phase 2
- Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis PatientsCompletedNCT00884169Phase 2